Blind Chef, Restaurateur, and Author Christine Há Spearheads ‘NMOSD Won’t Stop Me’ Initiative
Award-winning chef Christine Há, who is blind as a result of her NMOSD, is the public face of a new initiative called “NMOSD Won’t Stop Me.”
NMOSD Features
CAD Features, CC Features, Features, LAL-D Features, MG Features, MS Features, MTC Features, NMOSD Features, SCD Features
Rare Disease Day 2022: Health Care Policy and Protections Still Lacking in Many States
NORD and other rare disease organizations around the world will celebrate Rare Disease Day on February 28, 2022, with most events being held virtually.
A Quest to Understand Why NMOSD Disproportionately Affects the Black Population
People of African origin are 2-3 times more likely than Caucasians to develop NMOSD. Evanthia Bernitsas, MD, has spent much of her career trying to understand why.
The Role of IL-6 in Neuropathic Pain in Neuroimmunological Disorders
Neuropathic pain is frequent in NMOSD patients and conventional medications for neuropathic pain management have limited efficacy, a review shows.
Newly Approved Therapies Bring Hope to Patients With NMOSD
The Guthy-Jackson Charitable Foundation and the Siegel Rare Neuroimmune Association are racing to find a cure for neuromyelitis optica spectrum disorder (NMOSD).
CORD Aims to Improve Diagnosis, Drug Access for Canada’s Rare Disease Patients
The Canadian Organization for Rare Disorders advocates for better diagnosis and drug access for Canada’s 3 million people with rare diseases.
AATD Features, ALGS Features, CAD Features, CC Features, CF Features, DMD Features, Features, GIST Features, HEM Features, IPF Features, LAL-D Features, LCFAOD Features, MG Features, NMOSD Features, PAH Features, Pompe Features, SCD Features, SMA Features
Israel Emerges as Global Powerhouse in Rare Disease Research
When it comes to rare disorders, Israel—a New Jersey-sized nation of 9.3 million that’s made headlines this year for its highly successful coronavirus vaccination campaign—is clearly an emerging powerhouse.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...